NVOS Stock News Today: Price, Updates & Analysis
If you’ve typed “NVOS stock news today” into Google, you’re probably one of two people: a longtime shareholder trying to figure out what’s left of a position that’s been battered for years, or someone who just spotted the ticker on a penny-stock forum and wants to know what they’re actually looking at. Either way, fair question. Novo Integrated Sciences (NVOS) has gone from a Nasdaq-listed healthcare company to a sub-penny OTC name in the span of a couple of years, and the story behind that move matters more than any single day’s price tick.
This piece walks through where NVOS trades right now, what’s been happening with the business, why the chart looks the way it does, and the specific risks anyone holding or watching this stock should understand.
Quick NVOS Snapshot
| Metric | Value |
| Ticker | NVOS |
| Exchange | OTC Markets (moved off Nasdaq) |
| Recent price | Roughly $0.003–$0.0035 per share |
| 52-week range | About $0.0001 – $0.06 |
| Market cap | Under $100,000 |
| Revenue (TTM) | ~$13.3 million |
| Net income (TTM) | Approximately -$16.2 million |
| Shares outstanding | ~19.7 million (post reverse split) |
| Sector | Healthcare services (physiotherapy, rehab, home care) |
| CEO | Robert Mattacchione |
Prices and figures shift daily on a stock this thin — always check a live quote source such as Yahoo Finance, Nasdaq, or your broker before making any decision. Numbers above reflect mid-2026 data and are for context, not a trading signal, visit more.
What Novo Integrated Sciences Actually Does
It reports through two segments: Healthcare Services and Product Sales. That’s worth remembering, because it’s easy to assume a stock trading at fractions of a cent has no underlying business at all. NVOS does — it’s just a business that hasn’t been able to translate revenue into profit, or investor confidence into a stable share price.
For readers who want the fuller company breakdown, our comprehensive overview of Novo Integrated Sciences digs into the subsidiary structure and how the two segments fit together.
Why NVOS Stock Has Collapsed
This is the part most people searching for NVOS news actually want answered. A few things happened, more or less in sequence:
Chronic share dilution: Novo has repeatedly raised cash through securities purchase agreements and promissory notes rather than through profitable operations. Every new round of financing added shares to an already growing count, and each addition chipped away at what existing holders owned.
A reverse split that didn’t fix the underlying problem: The company executed a 1-for-10 reverse split in November 2023, a common move for companies trying to lift their share price back above exchange minimums. Reverse splits change the number on the ticker; they don’t change the business fundamentals, and NVOS kept sliding afterward.
Persistent losses: Trailing twelve-month revenue sits around $13.3 million, which sounds like a real number until you see the roughly $16 million in net losses sitting next to it. A company burning more cash than it brings in eventually has to either raise money (more dilution) or cut costs — and the market has priced in a lot of uncertainty about which path wins out.
Delisting pressure: NVOS faced compliance issues with Nasdaq’s minimum listing standards and has since traded on the OTC market, where liquidity is thinner and institutional interest is close to nonexistent. That alone tends to depress valuation, independent of how the underlying clinics are performing.
For a deeper look at the mechanics behind these swings, see our analysis of the volatility in Novo Integrated Sciences’ stock price.
Recent Corporate Activity
Some of the more notable announcements from Novo Integrated Sciences over the past couple of years include:
- Multiple securities purchase agreements to raise short-term capital, including a $6.21 million financing round
- A standby letter of credit (SBLC) monetization program involving HSBC, intended to generate liquidity against a financial instrument rather than through equity sales
- A board-approved stock repurchase program, later expanded to $10 million on paper — though buybacks on a stock this thinly traded carry limited real-world impact
- Leadership changes, including Robert Oliva’s appointment as President
- Partnership and consulting agreements through subsidiaries, including work with India-based Futura Surgicare and Psychocare Health
None of these moves has meaningfully reversed the stock’s trajectory so far, which is a pattern worth watching rather than a guarantee of what happens next.
How to Track NVOS Stock News Today
Because this is a low-float, low-liquidity stock, prices can move sharply on small volume, and stale information spreads fast on social platforms. A few sensible habits:
- Check a live quote before reading any price into a headline: Numbers you see on aggregator sites can lag by minutes or be quoted from a different session.
- Read the actual press release, not just the headline: Business Wire and SEC filings are the primary sources — social sentiment tends to run ahead of the facts on names like this.
- Watch share count, not just share price: With a stock this diluted, tracking shares outstanding over time tells you more about real dilution than the price chart alone.
- Compare sentiment across platforms: If you also follow retail sentiment on other volatile tickers, our NVOS Stocktwits roundup tracks what retail traders are actually saying in real time, and it’s worth cross-referencing against the fundamentals above rather than trading on chatter alone.
If you’re new to this ticker altogether, our main NVOS stock overview page and the dedicated NVOS price and analysis page are good starting points before diving into daily headlines.
Is NVOS Stock a Buy Right Now?
Short answer: that’s not something anyone should decide from a blog post, and we’re not going to pretend otherwise. What can be said plainly is that NVOS sits in classic distressed-microcap territory — real revenue, real losses, heavy dilution history, thin liquidity, and a price that can double or halve on volume that wouldn’t move a mid-cap stock by a rounding error. Some traders specifically look for that kind of volatility.
Most long-term investors avoid it for good reason. If you’re weighing a position, treat anything below is a starting point for your own research, not a substitute for it — and size any position with the assumption that you could lose the entire amount.
FAQs About NVOS Stock
What is NVOS stock?
NVOS is the ticker symbol for Novo Integrated Sciences, Inc., a healthcare services company operating physiotherapy, rehabilitation, and related clinics primarily in Canada.
Why did NVOS stock drop so much?
A combination of repeated share dilution through financing rounds, persistent net losses despite steady revenue, a 2023 reverse stock split, and a move from Nasdaq to OTC markets after failing to meet listing standards.
Is NVOS still listed on Nasdaq?
No. The stock now trades over-the-counter (OTC) after facing Nasdaq compliance and delisting pressure.
Does Novo Integrated Sciences make money?
The company generates meaningful revenue — around $13 million trailing twelve months — but has posted substantial net losses in the same period, so no, it is not currently profitable.
How many shares of NVOS are outstanding?
Roughly 19.7 million shares outstanding, following the November 2023 1-for-10 reverse split. This number has moved with subsequent financing activity, so check a current filing for the latest count.
Where can I find official NVOS news?
Company press releases go out through Business Wire and are filed with the SEC. Aggregator sites and stock forums repost this information, sometimes with a delay, so the primary source is always the safer read.
Conclusion
NVOS stock news today rarely tells the full story if you only look at a single price movement. The bigger picture is a real operating healthcare business that has struggled to convert revenue into anything resembling shareholder value, weighed down by dilution, a reverse split, and a delisting from its original exchange.
None of that means the story is over — companies in distressed situations do occasionally turn things around — but it does mean anyone following this ticker should be reading filings and press releases directly rather than reacting to headlines alone.
For continuing coverage, bookmark our NVOS stock hub for updates, or reach out through our contact page if you have a specific question about the company’s filings history.
